Search
Search Results
##search.searchResults.foundPlural##
-
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3215PDF: 952HTML: 2599 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
1941PDF: 589HTML: 358 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1327PDF: 1102HTML: 245 -
THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2320PDF: 913HTML: 2013Fig 1 Rossi: 211 -
CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,
3818PDF: 1515HTML: 323 -
MUTATIONAL PROFILES OF F8 AND F9 IN A COHORT OF HAEMOPHILIA A AND HAEMOPHILIA B PATIENTS IN THE MULTI-ETHNIC MALAYSIAN POPULATION
2095PDF: 1079HTML: 911Figure 1: 178Figure 2: 196 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2250PDF: 1789HTML: 824 -
IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA? MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA
2612PDF: 1206HTML: 151 -
COEXISTENCE OF MULTIPLE GENE VARIANTS IN SOME PATIENTS WITH ERYTHROCYTOSES Multiple gene variants in erythrocytosis
901PDF: 1265HTML: 140 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2649PDF: 834HTML: 5361 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2262PDF: 2089HTML: 210 -
Idiopathic pulmonary embolism in a case of severe family ANKRD26 thrombocytopenia
2298PDF: 858HTML: 964Patient’s family tree: 195 -
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA
2180PDF: 1956HTML: 521 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
4211Suppl. Files: 1199PDF: 1117Html: 248 -
HB H DISEASE CAUSED BY UNIPARENTAL DISOMY: FIRST REPORT OF THE αT-SAUDIΑ MUTATION IN THE CHINESE POPULATION
1066PDF: 637Html: 163Suppl. Files: 456 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1441PDF: 894HTML: 231 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1447HTML: 630PDF: 866 -
PEDIATRIC MASTOCYTOSIS: AN UPDATE Chldren' Mastocytosis
1933HTML: 1635PDF: 1138 -
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2942PDF: 886HTML: 6600Untitled: 256Untitled: 209Untitled: 232Untitled: 239 -
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
4500PDF: 3692HTML: 367 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2250PDF: 1648HTML: 450 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
4106PDF: 1573HTML: 9247Untitled: 292Untitled: 199Untitled: 184Untitled: 177Untitled: 199Untitled: 356 -
Can Polycythemia Vera evolve from Acute Myeloid Leukemia? A Case Report Showing a Simultaneous Minor JAK2 V617F Mutated Clone, De novo polycythemia vera following AML remission
1746PDF: 811HTML: 298 -
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment
1806PDF: 885HTML: 1148 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
1918PDF: 1029HTML: 219 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1635PDF: 1083HTML: 431 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2530HTML: 296PDF: 929 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1710PDF: 1130HTML: 166 -
FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-T Cells
1020PDF: 1246HTML: 123 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2351PDF: 1354HTML: 17193Bassan Fig.1: 158Bassan Fig.2: 251Bassan Fig.4: 150Fig.3: 220 -
APPROACHING THE TARGET: THE PATH TOWARDS AN EFFECTIVE MALARIA VACCINE
2655PDF: 1000HTML: 15128 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2450PDF: 1699HTML: 458 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3466PDF: 1321HTML: 2305Fi.1 Gritti.Rambaldi: 223 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4051PDF: 1079HTML: 3893Untitled: 185Cneo. Fig.1: 122Untitled: 114Untitled: 142Untitled: 148 -
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1323PDF: 797HTML: 357 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3805PDF: 1664HTML: 87







